CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience

Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma

(2018) Niels W. C. J. van de Donk et al.   BRITISH JOURNAL OF HAEMATOLOGY

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

(2017) S K Kumar et al.   LEUKEMIA

Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation

(2017) Federica Costa et al.   Oncotarget

Roles and Modalities of Ectonucleotidases in Remodeling the Multiple Myeloma Niche

(2017) Antonella Chillemi et al.   Frontiers in Immunology

Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma

(2016) T. Plesner et al.   BLOOD

Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma

(2016) Saad Z. Usmani et al.   BLOOD

APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment

(2016) Y.-T. Tai et al.   BLOOD

CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma

(2016) Inger S. Nijhof et al.   BLOOD

Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

(2016) P. Sonneveld et al.   BLOOD

Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma

(2016) J. Krejcik et al.   BLOOD

Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference

(2016) Christopher McCudden et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA)

(2016) Niels W.C.J. van de Donk et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma

(2016) E. Drent et al.   HAEMATOLOGICA

Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance

(2016) S. J. de Haart et al.   HAEMATOLOGICA

Monoclonal antibodies targeting CD38 in hematological malignancies and beyond

(2016) Niels W. C. J. van de Donk et al.   IMMUNOLOGICAL REVIEWS

Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma

(2016) N. W. C. J. van de Donk et al.   International Journal of Laboratory Hematology

The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor–Mediated Cross-Linking

(2016) Marije B. Overdijk et al.   JOURNAL OF IMMUNOLOGY

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

(2016) Sagar Lonial et al.   LANCET

Adenosine Generated in the Bone Marrow Niche Through a CD38-Mediated Pathway Correlates With Progression of Human Myeloma

(2016) Alberto L Horenstein et al.   MOLECULAR MEDICINE

Daratumumab and Blood-Compatibility Testing

(2016)   NEW ENGLAND JOURNAL OF MEDICINE

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

(2016) Philippe Moreau et al.   NEW ENGLAND JOURNAL OF MEDICINE

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

(2016) Meletios A. Dimopoulos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

(2016) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

International validation of a dithiothreitol (DTT)-based method to resolve the daratumumab interference with blood compatibility testing

(2016) Claudia I. Chapuy et al.   TRANSFUSION

Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma

(2016) E. Drent et al.   HAEMATOLOGICA

Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance

(2016) S. J. de Haart et al.   HAEMATOLOGICA

Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma

(2015) N. W. C. J. van de Donk et al.   BLOOD

Re-challenging with anti-CD38 monotherapy in triple-refractory multiple myeloma patients is a feasible and safe approach

(2015) Evren Alici et al.   BRITISH JOURNAL OF HAEMATOLOGY

SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide

(2015) H Jiang et al.   LEUKEMIA

Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab

(2015) I S Nijhof et al.   LEUKEMIA

Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma

(2015) Marije B Overdijk et al.   mAbs

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

(2015) Sagar Lonial et al.   NEW ENGLAND JOURNAL OF MEDICINE

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

(2015) A. Keith Stewart et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

(2015) Henk M. Lokhorst et al.   NEW ENGLAND JOURNAL OF MEDICINE

When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy

(2015) Marlies Oostendorp et al.   TRANSFUSION

Resolving the daratumumab interference with blood compatibility testing

(2015) Claudia I. Chapuy et al.   TRANSFUSION

Unraveling the contribution of ectoenzymes to myeloma life and survival in the bone marrow niche

(2014) Valeria Quarona et al.   Annals of the New York Academy of Sciences

How I treat smoldering multiple myeloma

(2014) I. M. Ghobrial et al.   BLOOD

Fc -receptor-mediated trogocytosis impacts mAb-based therapies: historical precedence and recent developments

(2014) R. P. Taylor et al.   BLOOD

Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib

(2014) I. S. Nijhof et al.   CLINICAL CANCER RESEARCH

SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies

(2014) J. Deckert et al.   CLINICAL CANCER RESEARCH

Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide

(2014) I. S. Nijhof et al.   HAEMATOLOGICA

Diagnosis and Risk Stratification in Multiple Myeloma

(2014) Niels W.C.J. van de Donk et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients

(2013) Niels WCJ van de Donk et al.   EXPERT OPINION ON PHARMACOTHERAPY

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

(2013) Jesus San Miguel et al.   LANCET ONCOLOGY

Anti-CD20 Antibody Therapy for B-Cell Lymphomas

(2012) David G. Maloney   NEW ENGLAND JOURNAL OF MEDICINE

NAADP Mediates Insulin-Stimulated Glucose Uptake and Insulin Sensitization by PPARγ in Adipocytes

(2012) Eun-Kyung Song et al.   Cell Reports

CD38 and chronic lymphocytic leukemia: a decade later

(2011) F. Malavasi et al.   BLOOD

Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma

(2011) N W C J van de Donk et al.   LEUKEMIA

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

(2011) S K Kumar et al.   LEUKEMIA

Multiple Myeloma

(2011) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies

(2011) M S van der Veer et al.   Blood Cancer Journal

Treatment of relapsed and refractory multiple myeloma in the era of novel agents

(2010) Niels W.C.J. van de Donk et al.   CANCER TREATMENT REVIEWS

Interference of Monoclonal Antibody Therapies with Serum Protein Electrophoresis Tests

(2010) C. R. McCudden et al.   CLINICAL CHEMISTRY

Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab

(2010) M. S. van der Veer et al.   HAEMATOLOGICA

Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors

(2010) M. de Weers et al.   JOURNAL OF IMMUNOLOGY

Unknown

(2009) Alberto Horenstein et al.   MOLECULAR MEDICINE

Pathogenesis and treatment of renal failure in multiple myeloma

(2008) M A Dimopoulos et al.   LEUKEMIA

Evolution and Function of the ADP Ribosyl Cyclase/CD38 Gene Family in Physiology and Pathology

(2008) Fabio Malavasi et al.   PHYSIOLOGICAL REVIEWS

Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma

(2007) Ya-Wei Qiang et al.   BONE